Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:ARQT 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares fell 5.3% to $28.29 Friday after an early surge, tracking a shift in rate expectations following a soft U.S. jobs report. Broader biotech indexes rose. Investors are watching for Arcutis’ next earnings on Feb. 24 and an FDA decision on ZORYVE for children by June 29. The Fed’s late-January meeting remains a key focus for traders.
9 January 2026
···
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics shares closed up 3.4% at $29.04 in the final trading session of the year. A Form 144 filing showed Chief Medical Officer Patrick Burnett plans to sell 1,697 shares after acquiring them through restricted stock vesting. U.S. stock markets are closed Thursday for New Year’s Day and reopen Friday. The stock’s move contrasted with a broader market pullback.
1 January 2026
·

Stock Market Today

  • Hunter Douglas NV Stock Volume Surges 128x to 107,100 Shares on EURONEXT
    March 20, 2026, 9:33 AM EDT. HUNDP.AS, Hunter Douglas NV listed on EURONEXT, saw a massive intraday volume spike of 107,100 shares traded, marking a 128.57-fold increase over its 50-day average of 833 shares. The stock price hovered at €0.398 today, moving between €0.36 and €0.40, surpassing the 50-day average of €0.32 and nearing the 200-day average of €0.41. This unusual trading activity drew significant short-term attention despite no new earnings news. Meyka AI rated the stock C+ with a HOLD recommendation and projects a 12-month target of €0.60, implying 50.75% upside. Analysts suggest watching volume above 50,000 next session to confirm momentum, with risk controls advised due to limited liquidity and disclosure. Sector headwinds and low public financial data present notable risks. Traders should frame decisions within recent price volatility and technical levels.
Go toTop